FDA approves VYALEV for adults living with advanced parkinson's disease
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024
Prednisolone Acetate Ophthalmic Suspension is the first generic version of Pred Forte
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
He will join in place of Anil Arora, current President- Formulations Operations who will be superannuating in November, 2024
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
Strokes are affecting approximately 1.8 million people annually
Indoco is comprehensively working on the remedial action plan
Paliperidone extended-release tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
We now rank 3rd in pharmaceutical production by volume and 14th by value
Subscribe To Our Newsletter & Stay Updated